Correct usage and dosage of Datopotamab

Datopotamab (Datopotamab) is an antibody-drug conjugate (ADC) based on the Trop-2 target. It accurately identifies tumor cells (breast cancer, lung cancer) through antibodies, and then delivers the topoisomerase inhibitor payload into the cells to achieve stable and sustained anti-tumor effects. Due to its complex drug structure, there are strict requirements on the administration method, dose setting and infusion rhythm. The correct usage and dosage not only affects the effectiveness of the medicine, but is also highly related to safety.

According to overseas ADC medication guidance, the recommended dose of dabrotuzumab is 6 mg/kg, which is suitable for most adult patients. To avoid excessive drug exposure when patients weigh 90 kg or more, the maximum dose is limited to 540 mg. This type of ADC usually adopts a dosing mode based on body weight, which can maintain relatively stable pharmacokinetic levels among people of different body types.

Dedabrotuzumab must be administered by intravenous infusion instead of intravenous bolus injection or rapid infusion. The infusion interval is once every 3 weeks (a cycle of 21 days). This scheduled dosing mode is also a common protocol for most ADCs around the world. It can provide the body with sufficient recovery time under the premise of strong cytotoxic load, so that patients can maintain acceptable tolerance during long-term treatment. Treatment is usually continued until disease progression or unacceptable adverse effects occur. Judging from overseas experience, many patients will gradually monitor blood, liver function and eye conditions during multi-cycle treatment in order to adjust the infusion speed or cycle in a timely manner.

Before use, the medical team usually gives anti-allergy, anti-nausea and other pre-treatment drugs to reduce the risk of infusion reactions. In addition, it is recommended to appropriately extend the observation time for the first infusion. Once an infusion reaction occurs, the speed can be adjusted or the infusion can be suspended.

Reference materials:https://dailymed.nlm.nih.gov/